Vildagliptin + Metformin HydrochlorideThird Party Manufacturing in India

Vildagliptin is a selective DPP-4 inhibitor that prevents the breakdown of incretin hormones like GLP-1 and GIP. This increases insulin secretion from pancreatic beta cells and reduces glucagon release from alpha cells, both in a glucose-dependent manner. Metformin works primarily by decreasing hepatic glucose production through AMPK activation, reducing intestinal glucose absorption, and improving peripheral insulin sensitivity. Together, the two drugs target complementary pathways: metformin addresses insulin resistance and hepatic glucose output, while vildagliptin enhances the body's own incretin response to meals. This dual mechanism provides superior glycemic control over either agent alone, with a lower risk of hypoglycemia compared to sulfonylurea-based combinations. The combination is particularly effective for patients with type 2 diabetes who have inadequate control on metformin monotherapy, as it addresses both the insulin resistance and the progressive beta-cell dysfunction characteristic of the disease.

Therapeutic Uses

Vildagliptin + Metformin Hydrochloride combination is prescribed for the treatment of type 2 diabetes mellitus (T2DM) in patients whose blood sugar is not adequately controlled on metformin alone. This fixed-dose combination helps improve glycemic control through complementary mechanisms, addressing both insulin resistance and impaired incretin response.

• Type 2 Diabetes Mellitus: The primary indication, used as second-line therapy when metformin monotherapy fails to achieve target HbA1c levels.
• Glycemic Control Adjunct: Suitable for patients who require additional HbA1c reduction beyond what metformin alone can provide.
• Combination Therapy: Can be used alongside diet, exercise, and other antidiabetic agents as part of a comprehensive management plan.

Why Manufacturers Choose Vildagliptin + Metformin

The Vildagliptin + Metformin fixed-dose combination is one of the most prescribed antidiabetic combinations in India, driven by the high prevalence of type 2 diabetes and the clinical preference for DPP-4 inhibitor-based therapies with favorable safety profiles. Indian manufacturers benefit from consistent demand across both the domestic market and export territories including Africa, Southeast Asia, and the Middle East. The combination offers multiple branding opportunities for PCD franchise partners, making it a staple product line for any contract manufacturer specializing in antidiabetic formulations.

This makes Vildagliptin + Metformin one of the most sought-after antidiabetic combinations for third party manufacturing in India, with consistent demand from both institutional buyers and franchise operators.